Nonalcoholic Steatohepatitis | Treatment Algorithms: Claims Data Analysis | US | 2024
The treatment of nonalcoholic steatohepatitis (NASH) (also known as metabolic dysfunction–associated steatohepatitis [MASH]) has enormous potential for growth owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis, cardiovascular disease, and cancer. Treatment is limited to off-label therapies that have scant evidence to support their prescribing for NASH. Consequently, there is a pressing need for effective drug treatments. With the launch of the first labeled / branded therapy on the horizon, we use claims data to examine how both newly diagnosed and recently treated NASH patients are being treated in the United States.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed NASH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NASH patients?
- How have off-label therapies like Novo Nordisk’s semaglutide been integrated into the treatment algorithm, and what is its source of business?
- What percentage of NASH patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of NASH patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Novo Nordisk, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Akero Therapeutics, Inventiva Pharma, Sagimet Biosciences, 89bio
Key drugs: Pioglitazone, SGLT-2 inhibitors, GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, vitamin E, metformin, ursodeoxycholic acid, statins
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
